A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Condition(s) studied

Investigational drug(s) / intervention(s)

LY4584180: administered orally

Rituximab: administered through IV infusion

Study summary

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Eligibility

Primary outcome measure(s)

• Number of Dose-Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities — Baseline up to Day 28
  Number of Dose-Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities
• Number of Participants with One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration — Baseline up to 3 Years
  Number of Participants with One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration
• To Evaluate the Preliminary Antitumor Activity of LY4584180: Objective Response Rate (ORR) — Baseline up to 3 Years
  To Evaluate the Preliminary Antitumor Activity of LY4584180: Objective Response Rate (ORR)

Trial sites (46)

+ 6 more sites — see the full list on the official registry below.